In contrast, PRMT5 is overexpressed in Chronic Myeloid Leukemia (CML) downstream of oncogenic BCR‐ABL signalling and its inactivation causes a substantial proliferative disadvantage in CML stem cells.96 This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.